Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)

• Published in: Discover. Oncology 2023-06, Vol.14 (1), p.90-90, Article 90
• Main Authors: Yoon, Wan-Soo, Chang, Jong Hee, Kim, Jeong Hoon, Kim, Yu Jung, Jung, Tae-Young, Yoo, Heon, Kim, Se-Hyuk, Ko, Young-Cho, Nam, Do-Hyun, Kim, Tae Min, Kim, Se Hoon, Park, Sung-Hae, Lee, Youn Soo, Yim, Hyeon Woo, Hong, Yong-Kil, Yang, Seung Ho
• Format: Article
• Language: English
• Subjects: Adenosine; Antidiabetics; Brain cancer; Cancer Research; Cancer therapies; Chemotherapy; Clinical study; Clinical Trial; Diabetes; Double-blind studies; Drug dosages; Glioblastoma; Insulin; Internal Medicine; Kinases; Laboratories; Medical prognosis; Medicine; Medicine & Public Health; Metformin; Molecular Medicine; NCT; NCT03243851; Oncology; Patient safety; Proteins; Radiation therapy; Radiotherapy; Surgical Oncology; Survival; Temozolomide; Therapeutics
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-023-00678-3

Purpose Glioblastoma (GBM) has a poor prognosis after standard treatment. Recently, metformin has been shown to have an antitumor effect on glioma cells. We performed the first randomized prospective phase II clinical trial to investigate the clinical efficacy and safety of metformin in patients with recurrent or refractory GBM treated with low-dose temozolomide. Methods Included patients were randomly assigned to a control group [placebo plus low-dose temozolomide (50 mg/m 2 , daily)] or an experimental group [metformin (1000 mg, 1500 mg, and 2000 mg per day during the 1st, 2nd, and 3rd week until disease progression, respectively) plus low-dose temozolomide]. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), disease control rate, overall response rate, health-related quality of life, and safety. Results Among the 92 patients screened, 81 were randomly assigned to the control group (43 patients) or the experimental group (38 patients). Although the control group showed a longer median PFS, the difference between the two groups was not statistically significant (2.66 versus 2.3 months, p  = 0.679). The median OS was 17.22 months (95% CI 12.19–21.68 months) in the experimental group and 7.69 months (95% CI 5.16–22.67 months) in the control group, showing no significant difference by the log-rank test (HR: 0.78; 95% CI 0.39–1.58; p  = 0.473). The overall response rate and disease control rate were 9.3% and 46.5% in the control group and 5.3% and 47.4% in the experimental group, respectively. Conclusions Although the metformin plus temozolomide regimen was well tolerated, it did not confer a clinical benefit in patients with recurrent or refractory GBM. Trial registration NCT03243851, registered August 4, 2017.